Detection of AD Biomarkers in Tear Fluid | NCT04620902 | Trialant
CompletedObservationalUpdated Nov 9, 2020
Detection of AD Biomarkers in Tear Fluid
Detection of AD Biomarkers in Tear Fluid
ClinicalTrials.gov ID
NCT04620902
Lead Sponsor
Maastricht University Medical CenterOTHER
Overall Status
Completed
Study Type
Observational
Enrollment
69Actual
Last Update Posted
Nov 9, 2020Actual
Start Date
Jan 1, 2018Actual
Primary Completion Date
Jan 1, 2020Actual
Completion Date
Jan 1, 2020Actual
Official Title
Detection of AD Biomarkers in Tear Fluid
Brief Summary
Detection of AD biomarkers in tear fluid
Cognitive Impairment
Tear sampling
Ages Eligible for Study
Child (0-17)Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
Yes
Eligibility Criteria
Inclusion Criteria:
. Inclusion criteria were an MMSE score ≥ 20 and a CDR score from 0 to 1, thereby including patients across the whole clinical spectrum (i.e. from subjective cognitive disorder to (mild) dementia).
Exclusion Criteria:
Exclusion criteria at baseline were neurological diseases (such as Normal Pressure Hydrocephalus, Morbus Huntington, brain tumor, epilepsy, encephalitis, recent Transient Ischemic Attack (TIA) or cerebrovascular accident (CVA) (< 2 years), or TIA/CVA with concurrent (within three months) cognitive decline) and a history of psychiatric disorders (such as schizophrenia, bipolar disorder or psychotic problems, current major depressive disorder (within 12 months), or alcohol abuse).